Naftifine Hydrochloride
NDC 70700-161
Product Information
Naftifine Hydrochloride is a ANDA-approved product labeled by Xiromed, Llc. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a product. This product entry covers the primary NDC 70700-161 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 70700-161?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- NAFTIFINE HYDROCHLORIDE (UNII: 25UR9N9041)
- NAFTIFINE (UNII: 4FB1TON47A) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BENZYL ALCOHOL (UNII: LKG8494WBH)
- CETYL ALCOHOL (UNII: 936JST6JCN)
- CETYL ESTERS WAX (UNII: D072FFP9GU)
- ISOPROPYL MYRISTATE (UNII: 0RE8K4LNJS)
- POLYSORBATE 60 (UNII: CAL22UVI4M)
- WATER (UNII: 059QF0KO0R)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)
- STEARYL ALCOHOL (UNII: 2KR89I4H1Y)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1246096 - naftifine HCl 2 % Topical Cream
- RxCUI: 1246096 - naftifine hydrochloride 20 MG/ML Topical Cream
- RxCUI: 1246096 - naftifine hydrochloride 2 % Topical Cream
* Please review the full disclaimer at the bottom of this page.
Patient Education
Naftifine Topical
Naftifine is used for skin infections such as athlete's foot, jock itch, and ringworm. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
[Learn More]
* Please review the full disclaimer at the bottom of this page.